NASDAQ: CASI | 中文 | Contact Us

Other Assets

CASI’s assets include a small portfolio of FDA-approved and FDA-pending ANDAs for generic products.

For the treatment of chronic hepatitis B virus infections

Product Approved
Entecavir tablets X
Tenofovir disoproxil fumarate (TDF) tablets X

Product Approved
Benazepril tablets X
Bisoprolol fumarate tablets X
Burprenorphine HCL Sublingual tablets X
Cefprozil tablets X
Cilostazol tablets – 50mg X
Cilostazol tablets – 100mg X
Desvenlafaxine ER tablets X
Diclofenac potassium 50mg tablets X
Diclofenac sodium DR 25mg, 50mg tablets X
Diclofenac sodium DR 75mg tablets X
Heparin sodium for injection X
Methimazole tablets X
Nabumetone tablets X
Ondansetron HCL tablets X
Repaglinide tablets X
Tizanidine tablets X

Product Pending
Aripiprazole tablets X
Bepotastine Ophthalmic Solution X
Bromfenac Ophthalmic Solution X
Telmisartan and hydrochlorothiazide tablets X

About Us

CASI is a U.S. NASDAQ-listed biopharmaceutical company with a platform to develop and accelerate the launch of pharmaceutical products and innovative therapeutics in China, the U.S., and throughout the world. We have offices in Rockville, Maryland, and a wholly owned subsidiary in Beijing, China, through which substantially all of our operations are conducted.

Learn More